Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
about
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolismEdoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous ThromboembolismManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyAn evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillationSpecial considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillationGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentPharmacology of anticoagulants used in the treatment of venous thromboembolismClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyEdoxaban: an update on the new oral direct factor Xa inhibitor.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Edoxaban: an investigational factor xa inhibitor.Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits.Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.Edoxaban.Managing patients taking edoxaban in dentistryPopulation pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 studyPharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism.Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.Edoxaban: a focused review of its clinical pharmacology.Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review.Direct oral anticoagulants: integration into clinical practice.Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.Target-specific oral anticoagulants and the hospitalist.The role of factor Xa inhibitors in venous thromboembolism treatment.Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.Edoxaban: a review in nonvalvular atrial fibrillation.Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.Drug interactions with new oral anticoagulants in elderly patients.Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
P2860
Q26746233-D473E0D3-5C5E-41DA-8CE8-BF5E029D5D30Q26764998-8B6720B7-A0BF-45DE-A57E-7028AC6065D4Q26766303-67323314-9DD2-42AC-BA74-911956BEE18EQ27027953-36BE5F8D-8DAF-40EE-BEDF-EDD88F6DC199Q28072542-6185542E-01D3-4C49-8F7A-A08B011D6746Q28076077-1FD40662-35BE-4F57-96D7-7C1EEE3C4469Q28078967-1FA79DF7-FC14-4F36-8033-C10F845450A8Q30234940-B0EBA848-90A7-4974-9976-0FE73FA83D1FQ33891915-897F338D-24E7-4767-ABC5-0FFFFA59A765Q33935409-3DB16BD8-7047-40B4-9E0F-F6889144FA53Q34109813-252A0CD9-00B3-4E02-A1CA-C5329EDF520FQ34306430-57A32D58-3D2B-40A7-8E91-036D04A96927Q35746798-9C6C75FC-86F7-46E7-B90E-2AECC360BE90Q35807991-C9FBBFD6-DE97-460C-88E4-9182E0DBE2A9Q35986742-F8D3652B-7A7D-4828-B140-FF5A2B6AC348Q36100271-44AB2744-5C0A-4276-9B9E-1965A3273C01Q36109959-92D38313-A0FD-4DF6-A42F-785F6B40DD16Q36283741-D8F7B77B-098A-49B2-B031-B2E3D7360067Q36410089-60A90A13-B79E-41BE-A9FB-EE09DDF2393BQ36541731-AFC65D57-81CC-40A1-BDAF-17206B7DABB3Q36691249-B62E79E8-D618-46F8-97B2-636A6E85E65EQ36840816-F9D78EAF-FEAD-42C4-AB9B-0B80E9DF99DAQ37114565-888A05F6-C1BC-439A-B1D2-FF08F67E8EF5Q37399582-206BCE1C-D6F3-4FC0-B214-59A042E2E171Q38182640-6A54B12E-D284-4057-9F4C-B3F108532D01Q38210326-66021BE3-F19C-4D5B-B296-027F3BE75C90Q38216837-6F354B40-0910-4046-837C-76FE1D3D615EQ38228212-23ECDF3C-3E49-486B-AD3B-954C5D259991Q38263224-08C41595-C245-4EE1-BC5B-FD271B2B69E4Q38307541-1CE2298E-9EB8-4354-9216-A89FD5C94A67Q38352438-2A7335DF-E2FC-4400-BBDD-2F9BB7011C26Q38386660-871413F0-4542-4AA7-8D59-D39867940250Q38495958-C9A5AEC3-B861-48F4-B4D4-98D7C3230EB3Q38525918-506D30B1-B516-4762-B6D8-64D868A8B590Q38566808-F3EA114C-0A1D-485F-B3C4-22A281667249Q38586582-A4D6D34B-22D3-427F-87B1-BAC75C2FBD2CQ38588261-322ADF88-B1CD-4B53-B0DA-26FA6E233F9BQ38616215-945464AF-8288-4D54-9202-B745CC7FEDF5Q38627495-BE9D051C-B23C-4D8B-BF11-B6E01345ACB6Q38630768-93578926-504D-41F6-9501-DECF01E379DD
P2860
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@ast
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@en
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@nl
type
label
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@ast
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@en
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@nl
prefLabel
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@ast
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@en
Drug-drug interaction studies ...... , an oral factor Xa inhibitor.
@nl
P2093
P2860
P1476
Drug-drug interaction studies ...... n, an oral factor Xa inhibitor
@en
P2093
George Zhang
Hamim Zahir
Jeanne Mendell
Minggao Shi
Nobuko Matsushima
Shuquan Chen
P2860
P2888
P304
P356
10.1007/S40256-013-0029-0
P577
2013-10-01T00:00:00Z
P5875
P6179
1028775473